Black Diamond Therapeutics, Inc. (BDTX) Earnings History
Annual and quarterly earnings data from 2017 to 2025
Loading earnings history...
BDTX EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
BDTX Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
Download Data
Export BDTX earnings history in CSV or JSON format
Free sign-in required to download data
Black Diamond Therapeutics, Inc. (BDTX) Earnings Overview
As of May 6, 2026, Black Diamond Therapeutics, Inc. (BDTX) reported trailing twelve-month net income of $21M, reflecting +130.7% year-over-year growth. The company earned $0.38 per diluted share over the past four quarters.
Looking at the long-term picture, BDTX's historical earnings data spans multiple years. The company achieved its highest annual net income of $22M in fiscal 2025, representing a new all-time high.
Black Diamond Therapeutics, Inc. maintains positive profitability with. The company continues to generate positive earnings from operations. View revenue history →
Compared to peers including KYMR (-$315M net income, -794.4% margin), NUVL (-$381M net income), AUPH ($287M net income, 101.5% margin), BDTX has comparable earnings metrics. Compare BDTX vs KYMR →
BDTX Earnings vs Peers
Earnings metrics vs comparable public companies
BDTX Historical Earnings Data (2017–2025)
9 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $22M | +132.1% | $13M | $0.39 | - | - |
| 2024 | -$70M | +15.5% | -$79M | $-1.27 | - | - |
| 2023 | -$82M | +9.6% | -$86M | $-1.88 | - | - |
| 2022 | -$91M | +27.4% | -$93M | $-2.52 | - | - |
| 2021 | -$126M | -86.7% | -$127M | $-3.47 | - | - |
| 2020 | -$67M | -90.7% | -$70M | $-2.04 | - | - |
| 2019 | -$35M | -294.8% | -$9M | $-1.15 | - | - |
| 2018 | -$9M | -94.1% | -$9M | $-0.64 | - | - |
| 2017 | -$5M | - | -$4M | $-0.64 | - | - |
See BDTX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BDTX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare BDTX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonBDTX — Frequently Asked Questions
Quick answers to the most common questions about buying BDTX stock.
Is BDTX growing earnings?
BDTX EPS is $0.38, with earnings growth accelerating to +130.7%. This exceeds the 5-year CAGR of N/A. TTM net income reached $21M.
What are BDTX's profit margins?
Black Diamond Therapeutics, Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are BDTX's earnings?
BDTX earnings data spans 2017-2025. The accelerating earnings trend is +130.7% YoY. Historical data enables comparison across business cycles.